What’s next for Generation HD1 drug trial?
Ionis have today released a statement about the drug tominersen (a medicine designed to reduce the production of the huntingtin (HTT) protein) and its effect on Huntington’s disease. The drug’s Phase 3 trial was halted last year due to a decision by an independent data monitoring committee that was reviewing the trial. Their recommendation was to stop dosing, but continue to follow patients to better understand the impact of treatment on patients given the drug tominersen.
This new analysis of GENERATION HD1 suggests that tominersen may have potential benefit to some patients. Roche are at the early stages of designing a new Phase 2 clinical trial in younger adult patients with lower disease burden. This is someone in the earlier stages of the disease.
Here at Huntington's Disease Association we welcome these findings and are pleased that the drug may potentially offer some treatment for younger patients. However, it is disappointing that the drug has not been able to benefit everyone with Huntington's disease.
Cath Stanley, Chief Executive of Huntington's Disease Association said;
“We welcome the news that Roche and Ionis are able to continue to explore the use of tominersen in fighting Huntington’s disease. We look forward to the results of this next trial for younger people with early symptoms of Huntington's disease. Here at Huntington’s Disease Association, we will continue to support the work of pharmaceutical companies that are determined to find a treatment.”
Professor Hugh Rickards, Chair of Huntington's Disease Association said;
“Although there was great disappointment in the community when the trials were halted last year, there has been encouraging data to support a Phase 2 trial. Tominersen is just one of a number of compounds that are being investigated in Huntington disease and we will continue to keep our community up to date with the latest findings”
You can find out more about the results by attending the webinar organised by Roche on Monday 24 January at 5.00pm. You can register for the webinar here.
To hear about further developments, please sign up to our mailing list.
If you are affected by Huntington’s disease and need support or advice, please contact us on 0151 331 5444 or email [email protected].
Ionis have today released a statement about the drug tominersen (a medicine designed to reduce the production of the huntingtin (HTT) protein) and its effect on Huntington’s disease. The drug’s Phase 3 trial was halted last year due to a decision by an independent data monitoring committee that was reviewing the trial. Their recommendation was to stop dosing, but continue to follow patients to better understand the impact of treatment on patients given the drug tominersen.
This new analysis of GENERATION HD1 suggests that tominersen may have potential benefit to some patients. Roche are at the early stages of designing a new Phase 2 clinical trial in younger adult patients with lower disease burden. This is someone in the earlier stages of the disease.
Here at Huntington's Disease Association we welcome these findings and are pleased that the drug may potentially offer some treatment for younger patients. However, it is disappointing that the drug has not been able to benefit everyone with Huntington's disease.
Cath Stanley, Chief Executive of Huntington's Disease Association said;
“We welcome the news that Roche and Ionis are able to continue to explore the use of tominersen in fighting Huntington’s disease. We look forward to the results of this next trial for younger people with early symptoms of Huntington's disease. Here at Huntington’s Disease Association, we will continue to support the work of pharmaceutical companies that are determined to find a treatment.”
Professor Hugh Rickards, Chair of Huntington's Disease Association said;
“Although there was great disappointment in the community when the trials were halted last year, there has been encouraging data to support a Phase 2 trial. Tominersen is just one of a number of compounds that are being investigated in Huntington disease and we will continue to keep our community up to date with the latest findings”
You can find out more about the results by attending the webinar organised by Roche on Monday 24 January at 5.00pm. You can register for the webinar here.
To hear about further developments, please sign up to our mailing list.
If you are affected by Huntington’s disease and need support or advice, please contact us on 0151 331 5444 or email [email protected].